CML and the WHO: Why?
Ellin Berman(Memorial Sloan Kettering Cancer Center), Brian Druker(Howard Hughes Medical Institute), Vivian G. Oehler(University of Washington), Ravi Bhatia(City Of Hope National Medical Center), Moshe Talpaz(University of Michigan–Ann Arbor), Tiffany Tanaka(UC San Diego Health System), B. Douglas Smith(Johns Hopkins University), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Neil P. Shah(University of California, San Francisco), Michael J. Mauro(Memorial Sloan Kettering Cancer Center), Michael W. Drazer(Susan Thompson Buffett Foundation), Jessica K. Altman(Princess Margaret Cancer Centre), Leland Metheny(Cancer Institute (WIA)), Iskra Pusic(Washington University in St. Louis), Maria L. Amaya(University of Colorado Denver), Srinivas K. Tantravahi(University of Utah), Keith W. Pratz(Cancer Institute (WIA)), Lori J. Maness(Susan Thompson Buffett Foundation), Sanjay Mohan(Breast Cancer Research Foundation), Michael Styler(Fox Chase Cancer Center), Kendra Sweet(Moffitt Cancer Center), Peter Curtin(City Of Hope National Medical Center), Onyee Chan(Moffitt Cancer Center), Kebede H. Begna(Mayo Clinic), William Shomali(Stanford Medicine), Daniel J. DeAngelo(Dana-Farber Cancer Institute), David T. Yang(University of Wisconsin Carbone Cancer Center), Robert H. Collins(Texas Oncology), Jerald P. Radich(Fred Hutch Cancer Center), Steven Tsai(University of Colorado Cancer Center), JOSEPH EARLE MOORE(Duke Medical Center), Jeanna Welborn(UC Davis Comprehensive Cancer Center), Jennifer E. Vaughn(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michal G. Rose(Yale Cancer Center), Michael W. Deininger(Oregon Health & Science University)
Cited by 14
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k